Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. We provide a comprehensive, integrated and highly customizable range of active pharmaceutical ingredient, or API, and finished drug product services to our customers, from formulation development to clinical and commercial-scale manufacturing, packaging, and life cycle management. Our services address both small molecule and large molecule biological drugs. We believe we are the only end-to-end integrated provider of such services, which, combined with our scientific and regulatory expertise and specialized capabilities, allows our customers to partner with a single outsourced provider to address their most complex development and manufacturing needs. We believe we have the broadest technological capabilities in our industry, across the full spectrum of development and manufacturing, to support our end-to-end integrated platform. We believe we are a critical partner for our customers who increasingly rely on our customized formulation, development and manufacturing expertise to address growing drug complexity, cost pressures and regulatory scrutiny. We partner with many of our customers early in the drug development process, providing us the opportunity to continue to expand our relationship as molecules progress through the clinical phase and into commercial manufacturing. This results in long-term relationships with our customers and a recurring revenue stream. We believe our breadth of services, regulatory track record, reliability and scale address our customers’ increasing need to outsource and desire to reduce the number of supply chain partners while maintaining a high quality of service.
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Patheon Holdings Cooperatief U.A.
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Sep 17
SC 14D9/A
Tender offer solicitation (amended)
13 Sep 17
SC TO-T/A
Third party tender offer statement (amended)
13 Sep 17
8-K
Termination of a Material Definitive Agreement
5 Sep 17
25
Voluntary exchange delisting
1 Sep 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Aug 17
SC 14D9/A
Tender offer solicitation (amended)
29 Aug 17
SC TO-T/A
Third party tender offer statement (amended)
29 Aug 17
SC 14D9/A
Tender offer solicitation (amended)
23 Aug 17
SC TO-T/A
Third party tender offer statement (amended)
23 Aug 17
Latest ownership filings
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|